methacetin has been researched along with Complication, Postoperative in 3 studies
methacetin: RN given refers to parent cpd
methacetin : A member of the class of acetamides that is paracetamol in which the hydrogen of phenolic hydroxy group has been replaced by a methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this pilot study, methacetin breath testing predicted the risk of liver-related death and development/exacerbation of ascites more accurately than MELD ⩾15 or ⩾19." | 3.81 | Use of the methacetin breath test to classify the risk of cirrhotic complications and mortality in patients evaluated/listed for liver transplantation. ( Brown, K; Gordon, SC; Ilan, Y; Lalazar, G; Mizrahi, M; Reuben, A; Sanyal, A; Stravitz, RT, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wittauer, EM | 1 |
| Oldhafer, F | 1 |
| Augstein, E | 1 |
| Beetz, O | 1 |
| Kleine, M | 1 |
| Schumacher, C | 1 |
| Sieg, L | 1 |
| Eismann, H | 1 |
| Johanning, K | 1 |
| Bleich, A | 1 |
| Vondran, FWR | 1 |
| Jara, M | 1 |
| Bednarsch, J | 1 |
| Lock, JF | 1 |
| Malinowski, M | 1 |
| Schulz, A | 1 |
| Seehofer, D | 1 |
| Stockmann, M | 1 |
| Stravitz, RT | 1 |
| Reuben, A | 1 |
| Mizrahi, M | 1 |
| Lalazar, G | 1 |
| Brown, K | 1 |
| Gordon, SC | 1 |
| Ilan, Y | 1 |
| Sanyal, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 13C-Methacetin Breath Test for the Prediction of Outcome in in Acute Liver Injury or Acute Liver Failure[NCT02786836] | Phase 2/Phase 3 | 76 participants (Actual) | Interventional | 2016-06-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The relationship between the cPDR (cumulative PDR of metabolized 13C-Methacetin 20 minutes after ingestion) in single time points of MBT measurements and TFS and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: The first MBT reading either on Day 1 or Day 2 and Day 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Day 1 or 2 MBT/transplant free survival at Day 21 | Day 1 or 2 MBT & Day 21 non-TFS | |
| 13C-Methacetin Breath Test (MBT) | 1.4 | 0.2 |
Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 (normal carbon dioxide) ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS (transplant free survival) and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: Days 1 and 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Mean Peak PDR for TFS subjects at Day 21 | Mean Peak PDR for non-TFS subjects at Day 21 | |
| 13C-Methacetin Breath Test (MBT) | 10.2 | 1.9 |
This outcome is similar to the peak PDR defined in the primary outcome but as a secondary we are looking at Day 1 or Day 2 peak PDR values. Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: The first MBT reading either on Day 1 or Day 2 and Day 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Day 1 or 2 MBT & Day 21 TFS | Day 1 or 2 MBT & Day 21 non-TFS | |
| 13C-Methacetin Breath Test (MBT) | 9.1 | 2.3 |
1 review available for methacetin and Complication, Postoperative
| Article | Year |
|---|---|
[Enhancing safety in liver surgery using a new diagnostic tool for evaluation of actual liver function capacity - The LiMAx test].
Topics: Acetamides; Breath Tests; Cause of Death; Hepatectomy; Humans; Liver Diseases; Liver Failure; Liver | 2014 |
2 other studies available for methacetin and Complication, Postoperative
| Article | Year |
|---|---|
Porcine model for the study of liver regeneration enhanced by non-invasive 13C-methacetin breath test (LiMAx test) and permanent portal venous access.
Topics: Acetamides; Animals; Breath Tests; Carbon Isotopes; Disease Models, Animal; Feasibility Studies; Fem | 2019 |
Use of the methacetin breath test to classify the risk of cirrhotic complications and mortality in patients evaluated/listed for liver transplantation.
Topics: Acetamides; Aged; Ascites; Breath Tests; End Stage Liver Disease; Female; Humans; Liver Cirrhosis; L | 2015 |